ATLASAbbVie (ABBV) Q3 2026 earnings results
AbbVie (ABBV) reported EPS of $3.82 against an analyst estimate of $3.74: a beat of $0.08 (2.1%). The quarter ended Sep 30, 2026; the company reported on Friday, October 30, 2026, before the open.
Status: Confirmed · cross-checked Nov 2 · Source: EODHD (calendar and fundamentals, cross-checked)
Notify me when AbbVie reports
Track ABBV free Add AbbVie to a free ATLAS watchlist.
ABBV Q3 2026 results at a glance
| EPS reported | $3.82 |
|---|---|
| EPS estimate | $3.74 |
| Surprise | Beat · +$0.08 (+2.1%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Oct 30, 2026, before the open |
| Status | Confirmed · cross-checked Nov 2 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. This is AbbVie’s Q3 2026, a calendar-year company.
AbbVie EPS surprise history: last 3 quarters
AbbVie beat the EPS estimate in 2 of its last 3 reports, with an average surprise of +2.1%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Oct 30, 2026 | $3.74 | $3.82 | +2.1% | Beat | – |
| Jul 31, 2026 | $3.61 | $3.65 | +1.1% | In line | -4.8% |
| Apr 28, 2026 | $4.82 | $4.97 | +3.1% | Beat | +3.3% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
ABBV stock reaction to the report
ABBV moved +1.41% in the first session that reflects the report (close of Oct 29, 2026 $290.79 to close of Oct 30, 2026 $294.89). Since the report: -0.70% (latest close $288.75 on Nov 2, 2026, against $290.79 before the reaction).
Next ABBV earnings report
AbbVie has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the ABBV earnings calendar.
ATLAS fair value and signal for ABBV
| Last price | $288.75 (-2.1%) |
|---|---|
| ATLAS fair value | $156.39 (range $122.65–$199.42) · price is 85% above it |
| Chance of a higher close in 1 month | 53% (normal range $279.52–$300.66) |
These are model outputs from the same valuation and calibrated model as the AbbVie stock page. They describe an ordinary period and are not a forecast of any particular outcome.
AbbVie Q3 2026 earnings: frequently asked questions
Did AbbVie beat earnings estimates for Q3 2026?
AbbVie reported EPS of $3.82 against an analyst estimate of $3.74: a beat of $0.08 (2.1%).
When did AbbVie report Q3 2026 results?
AbbVie reported on Friday, October 30, 2026, before the open, for the quarter ended Wednesday, September 30, 2026.
How often does ABBV beat EPS estimates?
In its last 3 reports with a recorded result, AbbVie beat the EPS estimate 2 times; the average surprise was +2.1%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer